Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Organoids: their emerging essential role in pathological mechanisms and drug discovery of diabetes and its complications

Xu X., Zhang Y., Geng Y., Luo Y., Sun X.

Narrative Review on Chronic Kidney Disease, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Front Pharmacol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40926989
PMCID
PMC12414973
DOI
10.3389/fphar.2025.1650200

Abstract (original English)

Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research. We summarized the organoid models that have been developed for the study of diabetes mellitus and its complications, and describe their sources, establishment and maturation measures with a focus on pancreatic organoids. For the first time, we summarized the contribution of organoids in diabetes and its complications in terms of mechanism studies, drug screening, and cellular replacement therapies, in the hope of providing a feasible direction for personalized medicine and precision treatment of diabetes and its complications. In addition, we discuss the strengths and limitations of organoids in the field of diabetes and its complications. Nowadays, people strongly advocate personalized medicine and precision medicine, and in this regard, organoid technology has advantages that are unmatched by any conventional experimental models. By combing organoid technology with high-throughput technologies, "patient-specific" drug screening can b

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research